A critical need for therapies to improve survival amidst a growing threat

With the burden of cancer projected to grow significantly in the coming years, the need for effective therapies to meet healthcare requirements remains constant.

There were approximately 49,000 new cancer diagnoses in 20201, with this figure expected to rise to more than 98,000 by 20402.

Ministry of Health Malaysia, 2021

Early detection saves lives

The most common cancers, reported from 2012 to 2016, were cancers of the breast, colorectum, lung, lymphoma, nasopharynx, leukaemia, prostate, liver, cervix uteri and ovary.

Late diagnosis of cancer
(Stage 3 or 4)

Most common cancers in Malaysia

As a percentage of medically certified deaths (Department of Statistics Malaysia, 2021)1,3

0 %
Cool Number
0 %
Cancers of the colon, rectum and anus
0 %
Breast cancer


In 2012, Clinical Research Malaysia was established by the government to help clinicians in the country conduct impactful research and collaborate with top scientists around the world to bring innovative treatments to people with cancer in Malaysia.


In 2016, the National Strategic Plan for Cancer Control Programme was created to put a bigger emphasis on improving access to cancer care, diagnosis, treatment, and research. The government is also working to increase access to drugs by making them more affordable to patients.


According to the National Cancer Registry Report 2012–2016 released in 2020, there were nearly 30% more deaths from cancer compared to the 2007–2011 report.


2023 will mark the 20th anniversary of Malaysia’s National Cancer Control Plan, which implemented policies in cancer prevention, screening, early detection, treatment, and palliative care across the country.

Our Therapies

Our specialty pharmaceutical drugs for the domestic and international markets includes an oncology portfolio that comprises established products and newer biosimilar therapies, such as Kytron, Zuhera, Lebreta, Trevive and Krabeva.